Cochlear Downgraded to Sell on Structurally Weaker Growth, Demand Risks, and Margin Pressure

Citi analyst Laura Sutcliffe downgraded the rating on Cochlear to a Sell today, setting a price target of A$95.00.

Laura Sutcliffe has given his Sell rating due to a combination of factors including a materially weaker profit outlook and persistent demand risks. Cochlear’s FY26 earnings guidance was cut sharply, with management citing softer implant demand in developed markets, pressure on discretionary spending, and fewer upgrades from hearing aids, alongside regional, FX, and cost-related headwinds that compress margins.

Laura Sutcliffe’s rating is based on the view that these challenges will leave growth and profitability structurally lower for longer. She sees a slow recovery in implant volumes given reliance on adult patients, uncertain timing of any rebound in sentiment, potential procedure deferrals ahead of fully implantable devices, and no clear assurance Cochlear will lead that next product cycle, leading her to slash the target price and conclude the stock is still vulnerable to downside.

Based on the recent corporate insider activity of 9 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of CHEOF in relation to earlier this year.